TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05552287
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IFX will be given intravenously at 10 mg/kg at week 0, and 5 mg/kg at weeks 2, 4, and 8 to all patients (induction). Maintenance will start at week 12, and then ideally continue every 6 weeks till week 24 (end of study). IFX trough levels will be measured at weeks 4, 12, and 24. During the maintenance, the IFX dose and/or interval adjustments, the IFX discontinuation or the start of a co-medication (i.e., an immunomodulator) will be possible on indication (i.e., primary nonresponse, secondary loss of response, intolerance to study medication) at the physicians' discretion.
Study: NCT05572255
Drug: Cenobamate
Normalized name: Cenobamate
DrugBank: Cenobamate (DB06119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 200 mg Cenobamate Tablet
Study: NCT06796855
Drug: Intravesical Onabotulinum Toxin A Injection
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Participants in this arm will receive a single dose of 100 units of Onabotulinum Toxin A injected into 10 sites on the bladder wall using a 4mm injection needle and 19 Fr. rigid cystoscope. The injection is administered under local anesthesia in an outpatient setting. The Onabotulinum Toxin A is diluted in sterile saline and delivered into the detrusor muscle, aiming to reduce detrusor overactivity and urgency symptoms. Patients undergo urinary ultrasound and post-void residual volume (PVR) assessment on postoperative day 1 before discharge. No additional doses are administered, and follow-up visits are scheduled at 2, 4, and 12 weeks to evaluate symptom improvement and safety.
Study: NCT06536413
Drug: All-Trans Retinoic Acid (ATRA) Dose 0
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive oral ATRA 25 mg/m2 per day in two divided doses with carfilzomib-based regimens.~Eligible patients will enter the study in cohorts of two with the first cohort treated at Dose 0. To assign a dose to the next cohort of patients, dose escalation/de-escalation according to the the trials Bayesian Optimal Interval (BOIN) Design is conducted. In patients who respond and do not have any dose limiting toxicity (DLT), treatment will continue for a total of 6 cycles in the phase II expansion cohort and subsequently transitioned to standard -of-care options. Each cycle will be 28 days. In phase 1b, a minimum of 16 evaluable patients will be recruited and in the second phase a minimum of 26 evaluable patients will be recruited. A minimum of 42 evaluable patients will be recruited in the study.~If a dose limiting toxicity occurs at 25 mg/m2, then the dose will be reduced by 50% to 15 mg/sq m daily in two divided doses.
Study: NCT06536413
Drug: All-Trans Retinoic Acid (ATRA) Dose -1
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive oral ATRA 15 mg/m2 per day in two divided doses with carfilzomib-based regimens.~Eligible patients will enter the study in cohorts of two with the first cohort treated at Dose 0. To assign a dose to the next cohort of patients, dose escalation/de-escalation according to the trials Bayesian Optimal Interval (BOIN) Design is conducted. In patients who respond and do not have any dose limiting toxicity (DLT), treatment will continue for a total of 6 cycles in the phase II expansion cohort and subsequently transitioned to standard -of-care options. Each cycle will be 28 days. In phase 1b, a minimum of 16 evaluable patients will be recruited and in the second phase a minimum of 26 evaluable patients will be recruited. A minimum of 42 evaluable patients will be recruited in the study.
Study: NCT06793475
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carfilzomib 27mg/m\^2 will be administered by i.v. on Days 1,2,8,9 during bridging therapy.
Study: NCT06793475
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide (150mg/d) will be administered by p.o. on Days 1-14 during bridging therapy, and Days 1-28 every 28-day cycle during maintanance treatment.
Study: NCT06536413
Drug: All-Trans Retinoic Acid (ATRA) Dose 1
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive oral ATRA 45 mg/m2 per day in two divided doses with carfilzomib-based regimens.~Eligible patients will enter the study in cohorts of two with the first cohort treated at Dose 0. To assign a dose to the next cohort of patients, dose escalation/de-escalation according to the trials Bayesian Optimal Interval (BOIN) Design is conducted. In patients who respond and do not have any dose limiting toxicity (DLT), treatment will continue for a total of 6 cycles in the phase II expansion cohort and subsequently transitioned to standard -of-care options. Each cycle will be 28 days. In phase 1b, a minimum of 16 evaluable patients will be recruited and in the second phase a minimum of 26 evaluable patients will be recruited. A minimum of 42 evaluable patients will be recruited in the study.
Study: NCT06793475
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (20mg/d) will be administered by i.v. or p.o. on Days 1-4,8,9 during bridging therapy.
Study: NCT04958122
Drug: Cefixime 400mg
Normalized name: CEFIXIME 400MG TAB
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cefixime 400 mg, one capsule, twice a day for 10 days
Study: NCT05534750
Drug: Tedizolid arm (SIVEXTRO®)
Normalized name: Tedizolid
DrugBank: Tedizolid phosphate (DB09042)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be taken 1 tablet per day of 200 mg film-coated of Tedizolid (SIVEXTRO®), in the morning for 7 days. Then, the early bactericidal activity will be measured and compared to the other arms.
Study: NCT05534750
Drug: Linezolid arm (ZYVOXID®)
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be taken 2 tablets per day of 600 mg film-coated of Linezolid (ZYVOXID®) in the morning for 7 days. Then, the early bactericidal activity will be measured and compared to the other arms.
Study: NCT06219174
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg IV Q3 weeks
Study: NCT04973657
Drug: VK0214
Normalized name: VK0214
DrugBank: VK-0214 (DB17670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: API in capsule
Study: NCT05708755
Drug: Valganciclovir
Normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Delivered as standard of care for post-lung transplant immunosuppression and infection prophylaxis. Started on the first day post-transplant at a standard dose of 900 mg daily and continued for 12 months. Dose adjustments may be necessary based on renal function and/or adverse effects (e.g. neutropenia). Dose adjustments are standard based on package insert recommendations.
Study: NCT05473364
Drug: Acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diuretic and carbonic anhydrase inhibitor medication
Study: NCT06114238
Drug: Itepekimab AI
Normalized name: Itepekimab
DrugBank: Itepekimab (DB16206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Solution for injection; Route of administration: Subcutaneous AI
Study: NCT06114238
Drug: Itepekimab PFS
Normalized name: Itepekimab
DrugBank: Itepekimab (DB16206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Solution for injection; Route of administration: Subcutaneous PFS
Study: NCT05030441
Drug: Ivosidenib
Normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: . Patients should take ivosidenib at approximately the same time every day, with or without food, but should be instructed to avoid a high-fat meal as well as grapefruit and grapefruit products.
Study: NCT05609565
Drug: spinal anesthesia with hyperbaric prilocaine+adductor canal block (ACB) with bupivacaine
Normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: spinal anesthesia with hyperbaric prilocaine+adductor canal block (ACB) with bupivacaine
Study: NCT05609565
Drug: spinal anesthesia with bupivacaine
Normalized name: bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: spinal anesthesia with bupivacaine
Study: NCT06010719
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of Care. A 7-day, twice-daily course of amoxicillin will be offered as a syrup to children (80 mg/kg divided into twice-daily doses, estimated with weight-based dosing).
Study: NCT06794086
Drug: PD-1 Monoclonal Antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 monoclonal antibody is a type of immunotherapy drug designed to treat various cancers by targeting the programmed death receptor-1 (PD-1) pathway.The PD-1 monoclonal antibody used in this study is sintilimab at a dose of 200 mg, administered via intravenous infusion on Day 1. Participants will be considered eligible only if they have completed four or more cycles of PD-1 monoclonal antibody treatment both before and after SBRT.
Study: NCT06795204
Drug: Moxifloxacin Hydrochloride
Normalized name: Moxifloxacin Hydrochloride
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Positive Control
Study: NCT06184503
Drug: Velmanase Alfa
Normalized name: Velmanase alfa
DrugBank: Velmanase alfa (DB12374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamzede® (velmanase alfa, henceforth referred to as Lamzede) is a recombinant human lysosomal alpha-mannosidase product developed as an intravenous enzyme replacement therapy (ERT) for the treatment of alpha-mannosidosis.
Study: NCT06572111
Drug: BI 1839100
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1839100
Study: NCT06572111
Drug: BI 1839100 (C-14) formulation 2
Normalized name: Bis(2-benzothiazolyl) disulfide
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BI 1839100 (C-14) formulation 2
Study: NCT04995497
Drug: Intravenous Administration of Lidocaine Post Cardiac Surgery
Normalized name: post oak pollen extract
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine will be administered via intravenously. Initial dose will be at 2 mg/kg ideal body weight followed by dosing at 2 mg/kg/hr for 48 hours
Study: NCT04995497
Drug: Administration of Lidocaine Post Cardiac Surgery via ESP Catheter
Normalized name: post oak pollen extract
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine will be administered via ESP catheter. Initial dose will be at 2 mg/kg ideal body weight split between two catheters followed by dosing at 2 mg/kg/hr for 48 hours
Study: NCT06794866
Drug: OnabotulinumtoxinA
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Intramuscular Injections
Study: NCT06781879
Drug: Mitomycin c
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemoablation
Study: NCT06061809
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive 10mg/kg of Bevacizumab intravenously (IV) on Day 1 and Day 15 of each repeated cycle of treatment.
Study: NCT06061809
Drug: PD-L1 t-haNK
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive PD-L1 t-haNK (\~2 × 109 cells/infusion) intravenously (IV) on Day 1 and Day 15 of each repeated cycle of treatment.
Study: NCT06061809
Drug: N-803
Normalized name: N-803 COMPONENT IL-15R.ALPHA.SU/FC FUSION PROTEIN
DrugBank: Inbakicept (DB16479)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 1mg subcutaneously (SC) on Day 1 and Day 15 of each repeated cycle of treatment.
Study: NCT05737485
Drug: RCT1100
Normalized name: RCT1100
DrugBank: RCT1100 (DB18830)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCT1100 mRNA therapy supplied as varying dose strengths administered via oral inhalation using nebulizer
Study: NCT04607005
Drug: Mepolizumab
Normalized name: Mepolizumab
DrugBank: Mepolizumab (DB06612)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Mepolizumab will be available as a clear to opalescent, colorless solution for SC injection in a single-use, safety syringe at a unit dose strength of 100 mg/milliliters (mL).
Study: NCT06788158
Drug: Incobotulinum Toxin A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: will be administered 2 ampoules (200 IU) of Incobotulinum toxin , injectable solution presentation 100 IU ampoule with powder diluted in 1 ml of 0.9% saline solution in a single application at 4 points, in addition to a therapeutic exercise program in the teaching service to later do it at home that will be done daily for 4 months (cryotherapy for 15 minutes on the plantar fascia, active mobilizations of the ankle and foot for 5 minutes, stretching exercises for the triceps surae and plantar fascia for 20 seconds, 3 repetitions, strengthening of intrinsic muscles of the foot).
Study: NCT06796517
Drug: CAR-T Therapy
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: It uses the patient's own T cells, and requires a manufacturing process to modify and expand T cells before infusion. It directly targets B cell specific antigens, such as CD19 or CD20.
Study: NCT06796517
Drug: Bispecific antibody
Normalized name: Bispecific antibody 520c9x22
DrugBank: MDX-210 (DB17250)
Approvals — FDA: no, EMA: no, PMDA: no
Description: It uses a dual targeting mechanism to enhance specificity and immune activation. It is an off-the-shelf treatment, and doesn't require a manufacturing process of patient cells.
Study: NCT06796517
Drug: Antibody-Drug Conjugate
Normalized name: antibody-drug conjugate DP303c
DrugBank: DP-303c (DB17212)
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is a targeted therapy consisting of a monoclonal antibody linked to a cytotoxic drug. The antibody binds to a specific antigen on cancer cells, delivering the cytotoxic agent directly to the tumor, minimizing systemic toxicity.
Study: NCT06796517
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
DrugBank: Anti-GD2 monoclonal antibody 3F8 (DB15388)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibodies are lab-engineered antibodies that target specific antigens expressed on cancer cells. These commonly target CD20 (rituximab or obinutuzumab) to mediate immune destruction.
Study: NCT05126901
Drug: Ferric Maltol
Normalized name: Ferric Maltol
DrugBank: Ferric maltol (DB15598)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ferric maltol oral suspension: 150 ml amber glass bottle with graduated syringe and adaptor. Oral suspension containing 30 mg elemental iron, in the form of 231.5 mg ferric maltol, in 5 ml suspension~Study dosage: The dose of ferric maltol oral suspension that will be administered for children aged 1 month to \< 2 yrs: 0.1 ml/kg BID, 2 to - 11 yrs: 2.5 ml BID, 12-17 yrs: 5 ml BID.
Study: NCT05126901
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate 125 mg/ml (25 mg/ml elemental iron) oral liquid : 15 ml glass bottle.~Study dosage: For ferrous sulfate oral liquid, the dose administered will be for children and adolescents aged 2 years to 17 yrs: 6 mg/kg to the maximum of 4 ml BID.
Study: NCT05837091
Drug: Low Sodium Oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Titrated according to standard of care and continued on stable dose for 3 months
Study: NCT06483880
Drug: Albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive albendazole therapy at the recommended dosage.
Study: NCT06793332
Drug: Ivonescimab Combined With TROP2 ADC
Normalized name: miconazole
DrugBank: Ivonescimab (DB18931)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ivonescimab: 20 mg/kg, ivggt, day 1, every 3 weeks; Sacituzumab govitecan: 10 mg/kg, ivggt, day 1 and day 8, every 3 weeks;
Study: NCT02915198
Drug: Metformin XR
Normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The study medication dose may be increased by a step-wise fashion up to a maximum of 4 tablets per day.
Study: NCT05593029
Drug: SEP-363856
Normalized name: SEP-363856
DrugBank: SEP-363856 (DB15665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT05999396
Drug: Administration of CC-3
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated titration phase, Standard 3+3 titration phase, expansion phase
Study: NCT04720183
Drug: Sulfasalazine
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On Day 1, Day 5 and Day 9, a single oral dose of sulfasalazine tablets in fasted state.
Study: NCT05110495
Drug: Xentuzumab
Normalized name: Xentuzumab
DrugBank: Xentuzumab (DB14871)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study IMP is xentuzumab, a humanised IgG1 monoclonal antibody that neutralises the IGF ligands to inhibit activation of IGF-1R and INSR-A, suppressing IGF-mediated proliferation, invasion and therapy resistance
Study: NCT06679140
Drug: ibuzatrelvir
Normalized name: Ibuzatrelvir
DrugBank: Ibuzatrelvir (DB19451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuzatrelvir tablets
Study: NCT05538741
Drug: Bolus of remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.19-0.25 mg/kg for 60-80 years old 0.14-0.19 mg/kg for \>80 years old
Study: NCT06377696
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT06478212
Drug: Vorasidenib
Normalized name: Vorasidenib
DrugBank: Vorasidenib (DB17097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To be taken by mouth once daily in 28-day cycles with no break between cycles
Study: NCT06478212
Drug: Temozolomide (TMZ)
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: To be taken by mouth once daily for the first 5 days of each 28-day cycle, for a maximum of 12 cycles
Study: NCT05538741
Drug: Continuous infusion of remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 12 mg/kg/hr until loss of consciousness
Study: NCT04171817
Drug: Chlorhexidine
Normalized name: Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The goal of this work is to assess the effect of chlorhexidine (CHX)-based interventions--specifically use of pre-session chlorhexidine shampoo for the dog and use of chlorhexidine wipes on the dog's fur--on patient exposure to hospital-associated pathogens during the sessions with the dogs
Study: NCT04953780
Drug: Calaspargase pegol-mknl
Normalized name: calaspargase pegol-mknl
DrugBank: Calaspargase pegol (DB14730)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calaspargase pegol-mknl
Study: NCT04998604
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: solution for injection subcutaneous
Study: NCT04998604
Drug: Omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: solution for injection subcutaneous
Study: NCT05673057
Drug: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70)
Normalized name: Muromonab-Cd3
DrugBank: Muromonab (DB00075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase 1 comprises the dose-escalation part of the study and is designed to determine the recommended phase 2a dose regimen (RP2D-R) and/or the maximum tolerated dose-regimen (MTD-R) for MP0533 monotherapy.~Once the RP2D-R or MTD-R has been selected based on the dose escalation part, the study will proceed into the phase 2 expansion part and up to 30 additional patients will be treated.
Study: NCT05724329
Drug: Tislelizumab + Dasatinib + Quercetin (neoadjuvant)
Normalized name: Tislelizumab
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients receive Tislelizumab (IV) on day 1, dasatinib (PO) on day 1,2,3 and quercetin (PO) on day 1,2,3. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT05724329
Drug: Tislelizumab + Dasatinib + Quercetin (adjuvant)
Normalized name: Tislelizumab
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tislelizumab (200 mg, day=1) Cycle=1-15cycle Dasatinib (100mg/day, day= 1,2,3) Cycle=1、2、3、8、9、10 Quercetin (1250mg/day, day= 1,2,3) Cycle=1、2、3、8、9、10
Study: NCT06160284
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single dose of psilocybin administered in 20 mg or 25 mg doses depending on the participant's weight: 20 mg (among participants \< 70 kg) or 25 mg (among participants \>70 kg). Participants will be administered psilocybin at CNRU, within 1-2 weeks of the baseline \[11C\]-UCB-J PET.
Study: NCT06794450
Drug: Neostigmine + Atropine
Normalized name: atropine / neostigmine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient in active comparators arms will receive i.v. neostigmine 60 mcg/kg along with 0.4 mg of atropine sulfate per 1 mg of neostigmine at the end of operating procedure from the point at which a Train-of-Four Count (TOFC) of 2 is observed
Study: NCT06793150
Drug: dexmedetomidin
Normalized name: Dexmedetomidin
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A comparison will be made by maintaining one group with remifentanil and the other with dexmedetomidine.
Study: NCT04736966
Drug: Guselkumab 30mg
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 30mg of Guselkumab administered by subcutaneous injection
Study: NCT04736966
Drug: Guselkumab 70mg
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 70mg of Guselkumab administered by subcutaneous injection
Study: NCT04736966
Drug: Guselkumab 100mg
Normalized name: GUSELKUMAB 100MG/ML INJ 1ML SYR
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100mg of Guselkumab administered by subcutaneous injection